Skip to main content

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Tipranks - Tipranks - Sat Jan 17, 3:28AM CST

In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca, with a price target of p16,300.00.

Claim 70% Off TipRanks Premium

Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Roche Holding AG, and GlaxoSmithKline. According to TipRanks, Weston has an average return of 11.6% and an 81.05% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AstraZeneca with a p14,433.18 average price target.

See today’s best-performing stocks on TipRanks >>

Based on AstraZeneca’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of p15.19 billion and a net profit of p2.53 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p1.47 billion

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.

Read More on GB:AZN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).